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BACKGROUND: Recent work has demonstrated that c-Src and fully activated Y419Src expression was associated with poor clinical
outcome of breast cancer patients. It is unknown whether different activation stages of c-Src equally influence disease-specific survival
of breast cancer patients.
METHODS: Immunohistochemistry was performed on 165 resected breast cancers using antibodies to phosphorylated and
dephosphorylated Src kinase tyrosine site 530. Expression was assessed using the weighted histoscore method.
RESULTS: Majority of phosphorylated and dephosphorylated Y530Src expression was observed in the nucleus and cytoplasm.
Only 3.6% of phosphorylated Y530Src (pY530Src) expression was detected in the membrane, compared with 53%
with dephosphorylated Y530Src. Nuclear expression of pY530Src correlated negatively with oestrogen receptor (ER) status
(w
2 Po0.001), whereas cytoplasmic phosphorylated and dephosphorylated Y530Src expression correlated negatively with
membrane c-Src expression (w
2 P¼0.008, w
2 Po0.001). On univariate and multivariate analysis, no significant association was
noticed between phosphorylated or dephosphorylated Y530Src expression and disease-specific survival at any cellular location.
CONCLUSION: ER-negative breast cancer patients were more likely to express pY530Src in the nucleus. Breast cancer patients with
higher cytoplasmic expression of phosphorylated or dephosphorylated Y530Src were more likely not to express c-Src at the
membrane. Phosphorylated and dephosphorylated Y530Src expression is not associated with survival of patients.
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Src kinase is implicated as a regulator of cell proliferation and
survival, and as a contributor to cellular migration and invasion
(Frame, 2002). Recent work has demonstrated that cytoplasmic
c-Src and fully activated membrane Src phosphotyrosine 419
expression in breast cancer specimens was associated with poor
clinical outcome (Elsberger et al, 2009). c-Src is activated by a
number of pathways. The classical activation pathway includes
dephosphorylation of Y530 to initiate a configuration change of
the protein (partial activation), allowing full activation by
autophosphorylation of tyrosine site 419. Phosphorylation of the
tyrosine residue 530 on the c-terminal tail by Csk tyrosine kinase
acts as a negative regulatory protein-binding site, keeping Src
kinase in a closed confirmation (Roskoski Jr, 2005) and inactive.
The Src kinase can be found at different subcellular locations. It is
most abundantly localised in the cell cytoplasm, but is re-localised
to the membrane when activated. Subcellular localisation has also
been suggested to regulate Src activity (Bjorge et al, 2000). In
studies examining the role of Src in assembly of focal adhesions,
the inactive form of Src was localised to the perinuclear region of
cells in association with microtubules. On activation, Src was
transported to the plasma membrane where it is recruited to focal
adhesions (Fincham et al, 2000).
The aim of this translational study was to assess associations
between different stages of Src activation and expression pattern
with clinicopathological features of the cohort, cellular distribution
and their influence on breast cancer patients’ disease-specific
survival.
MATERIALS AND METHODS
Patients
A total of 314 patients were initially recruited. All patients were
diagnosed with operable invasive breast carcinoma between 1980
and 1999 in the Greater Glasgow area. These patients received
standard adjuvant treatment according to protocols at the time of
diagnosis. We included patients in our analysis only when all
clinical data, previous published c-Src expression data (Elsberger
et al, 2009) and phosphorylated and dephosphorylated Y530Src
kinase expression data were available (n¼165). Ethics approval
was granted by the local ethics committee.
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Tissue microarrays (TMAs) were already available for use in this
study. Cores of breast cancer tissue (0.6mm
2), identified by the
pathologist, were removed from representative areas of the tumour
taken from breast cancer patients at time of surgical resection. All
TMA blocks were constructed in triplicate.
Immunohistochemistry
Staining for ER (oestrogen receptor), PR (progesterone receptor)
and HER2 (human epidermal growth factor receptor) had been
previously performed for the cohort (Tovey et al, 2005). To
investigate the different stages of Src kinase activation, Clone28
antibody (Invitrogen, Paisley, UK) was employed to recognise the
partially activated form of Src, as Clone28 recognised Src that is
unphosphorylated at Y530, independent of the phosphorylation
status of Y419. To evaluate protein expression of inactive Src
kinase, anti-Src family negative regulatory [pY] site antibody
(Invitrogen) was used for detecting phosphorylated tyrosine site
530 (pY530Src). Antigen retrieval was performed in a preheated
antigen retrieval solution (citrate buffer (pH 6.0), Vector
Laboratories, Burlingame, CA, USA; Peterborough, UK), followed
by heating tissue sections under pressure for 5min in a microwave.
Endogenous peroxidase activity was blocked by incubation in
3% hydrogen peroxide. To reduce nonspecific binding, the
tissue sections were then incubated with 5% horse serum (Vector
Laboratories) in antibody diluent (DAKO Cytomation, Glostrup,
Denmark) for 20min at room temperature. Slides were incu-
bated with Clone28 (1:500) and anti-Src family negative regulatory
[pY] site antibody (1:1500) overnight at 41C. Signal was amplified
and visualised using the DAKO Envision Kit (DAKO Cytomation)
and DAB (Vector Laboratories). In each run, a positive and
negative isotype-matched control was included to ensure no false-
positive staining or intense stromal staining. Specificity of
antibodies was confirmed by western blotting. Protein expres-
sion of each core was assessed using the weighted histoscore
method (Kirkegaard et al, 2006). Over time and extensive section
cutting of the TMAs, tissue/cores vanished, resulting in a
decreased number for expression analysis. Each cellular location
was independently assessed for phosphorylated and dephosphory-
lated Y530Src kinase expression. Agreement between observers
was excellent and measured in interclass correlation coefficient
(all ICCC 40.83).
Statistical analysis
Medians of nuclear, cytoplasmic and membrane phosphorylated
and dephosphorylated Y530Src expression were used for statistical
analysis. Patients were split into groups with expression (above
median) and no expression (below or equal to the median).
Disease-specific survival rates were generated using the Kaplan–
Meier method. The log-rank test was used to compare significant
differences between subgroups using univariate analysis. To
remove a variable from the model, the corresponding P-value
had to be 40.05.
Inter-relationships among clinical parameters, phosphorylated
and dephosphorylated Y530Src and c-Src expression were
calculated using the w
2-test. The statistical analyses were
performed using a statistical software package (SPSS 15.0 Inc.,
Chicago, IL, USA).
RESULTS
Clinicopathological details
Clinicopathological features of the cohort are displayed in Table 1.
Mean patient follow-up was 7.1 years (minimum follow-up was 2.1
years and the maximum follow-up was 20 years).
pY530Src expression levels
Nuclear pY530Src expression was seen in the nucleus of 50% of
tumours investigated, cytoplasmic expression was observed in 44%
of tumours and only 3.6% of tumours investigated expressed
pY530Src in the membrane (Figure 1A).
Table 1 Correlations between clinicopathological features of the cohort, c-Src, phosphorylated and dephosphorylated Y530Src expression
Total patient cohort
v
2 P-values
314 Variables Numbers Cl28 nuc Cl28 cyto Cl28 memb Cl28 perinuc
Age (o50/450 years) 78/236 0.027* 0.906 0.547 0.239
Tumour type (duct/lob/tub/others) 298/10/3/3 0.307 0.304 0.394 0.269
Grade (G1/G2/G3) 22/146/146 0.312 0.010* 0.655 0.204
Size (o20, 20–50, 450mm) 126/169/19 0.901 0.030 0.565 0.016
Lymph node (positive/negative) 152/162 1.0 0.747 0.811 0.420
ER status (positive/negative) 209/105 0.055 0.535 0.806 0.645
PR status (positive/negative) 149/163 0.461 0.635 0.926 0.975
HER2 status (positive/negative) 51/263 0.628 0.038 0.306 0.181
c-Src nuc (positive/negative) 139/175 0.105 0.066 0.678 0.046
c-Src cyto (positive/negative) 139/175 0.740 1.0 0.811 0.629
c-Src memb (positive/negative) 135/179 0.841 o0.001* 0.393 0.002*
pY530Src nuc (positive/negative) 82/83 0187 0.428 0.848 0.406
pY530Src cyto (positive/negative) 73/92 0.282 0.001* 0. 703 o0.001*
pY530Src memb (positive/negative) 6/159 0.388 0.802 0.241 0.707
Clone28 nuc (positive/negative) 74/85 — o0.001 0.037 o0.001*
Clone28 cyto (positive/negative) 69/90 — — 0.081 o0.001*
Clone28 memb (positive/negative) 78/70 — — — 0.770
Abbreviations: c-Src¼Src kinase as accessed by an antibody to c-Src; Clone28¼Clone 28, Src kinase dephosphorylated at Tyrosine site 530; cyto¼cytoplasm; duct¼ductal
carcinoma; ER¼oestrogen receptor; lob¼lobular carcinoma; HER2¼human epidermal growth factor receptor 2; memb¼membrane; nuc¼nucleus; Perinuc¼perinucleus;
PR¼progesterone receptor; pY530Src¼anti-Src family negative regulatory [pY] site, Src kinase phosphorylated at Tyrosine site 530 (inactive form of Src); tub¼tubular
carcinoma. The above table shows the inter-relationship between phosphorylated and dephosphorylated Y530Src expression at different cellular levels and clinicopathological
characteristics of patients with breast cancer; Histology: others include mucinous, mucoid and micropapillary carcinoma; Grade: Bloom and Richardson grade. *negatively
correlated. Significant results are highlighted in bold. P-values of 40.01 were considered as non-significant due to the large number of statistical comparisons (Bonferroni
phenomenon).
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features of the cohort and pY530Src expression was detected; ER
status correlated negatively with nuclear expression of pY530Src
(w
2 Po0.001). Interestingly, cytoplasmic pY530Src correlated
negatively with membrane c-Src expression (w
2 P¼0.008). No
significant correlations were noted with membrane pY530Src
expression. Inter-relationships between the different pY530Src
cellular locations were insignificant. On univariate and multi-
variate analysis, there was no significant association noticed
between pY530Src expression and disease-specific survival at any
cellular location (nuclear P¼0.192, cytoplasmic P¼0.294 and
membranous P¼0.748).
Dephosphorylated Y530Src kinase expression levels
Perinuclear staining of dephosphorylated Y530Src was prominent
(Figure 1B) and was, therefore, included in the analysis. Nuclear
dephosphorylated Y530Src expression was witnessed in the
nucleus of 50% of tumours investigated and cytoplasmic expres-
sion was observed in 46% of tumours.
A remarkable 53% of tumours expressed dephosphorylated
Y530Src in the membrane and 55% of tumours expressed peri-
nuclear dephosphorylated Y530Src. No significant correlations were
noted between clinicopathological features and any of the depho-
sphorylated Y530Src expression sites. Nuclear and membrane
dephosphorylated Y530Src expression showed no significant correla-
tions with any of the other c-Src and pY530Src expressions. Inter-
relationship analysis of individual cellular locations demonstrated a
positive correlation between nuclear and cytoplasmic dephosphory-
lated Y530Src expression (w
2 Po0.001), and a negative correlation
between nuclear and perinuclear dephosphorylated Y530Src expres-
sion (w
2 Po0.001). As already observed with cytoplasmic pY530Src
expression, cytoplasmic dephosphorylated Y530Src correlated nega-
tively with membrane c-Src expression (w
2 Po0.001). Perinuclear
dephosphorylated Y530Src expression correlated negatively with
cytoplasmic pY530Src (w
2 Po0.001) and nuclear and cytoplasmic
dephosphorylated Y530Src (both w
2 Po0.001). No significant
association was noticed between dephosphorylated Y530Src expres-
sion and disease-specific survival at any cellular location (nuclear
P¼0.313, cytoplasmic P¼0.810, membranous P¼0.568 and peri-
nuclear region P¼0.625).
DISCUSSION
In vitro evidence for a role for c-Src in breast cancer is convincing,
but hardly supported by translational clinical studies. A preceding
study (Elsberger et al, 2009) revealed significant associations among
cytoplasmic c-Src, phosphorylated activated Y419Src kinase ex-
pressed in the membrane with shorter disease-specific survival,
increasing grade, tumour size, ER negativity and
HER2 positivity. These results support the role of Src kinase
expression and activation, currently described in the literature. To
expand the assessment of various phosphorylation sites of Src,
phosphorylated and dephosphorylated tyrosine site 530 was
investigated in this study. These antibodies should represent
c-Src in its inactive form and partially activated appearance. Clone28
has been used in previous studies (Sakai et al, 1998; Ito et al,2 0 0 1 ,
2002) to determine whether c-Src has a role in colorectal,
hepatocellular or mammary tumorigenesis. Intense staining was
frequently observed in colonic adenomas, as well as in well- and
moderately differentiated hepatocellular carcinomas and in colonic
adenocarcinomas at an early stage, suggesting that expression of
Clone28 was linked to an early event in carcinogenesis in situ before
invasive and metastatic elements manifest. Therefore, it is not
surprising that none of the expression patterns of phosphorylated
and dephosphorylated Y530 were significantly associated with
disease-specific survival of mixed breast cancer patient cohort.
Phosphorylated and dephosphorylated Y530Src were more or
less equally expressed in the nucleus and cytoplasm. However,
there was a noteworthy divergence of their expression at the cell
membrane. Phosphorylated Y530Src was rarely detected in the
membrane compared with dephosphorylated Y530Src, which was
mainly expressed in the membrane and perinuclear region,
corresponding with features seen in Sakai’s colonic tissue
immunohistochemistry study (Sakai et al, 1998).
Interestingly, cytoplasmic phosphorylated (inactive form) and
dephosphorylated Y530Src correlated negatively with membrane
c-Src expression (site of activation), confirming validity of results
regarding functional and cellular location, for example, the cell
membrane being site of Src activation.
Another negative correlation was observed between nuclear
expression of pY530Src and ER status (w
2 Po0.001), suggesting
that ER-negative breast cancer patients are more likely to express
inactive Src in the nucleus, valued as the site of inactivation.
In vitro experiments with c-Src showed that the oestradiol receptor
can activate c-Src, proposing that c-Src is an initial and integral
part of the signalling events mediated by the oestradiol receptor
(Migliaccio et al, 1996).
In this study, we determined that not only protein activation but
also stage and site of activation along with cellular location have an
important role for breast cancer patients. It also supports the
hypothesis that dephosphorylated Y530Src is more related to early
stages of carcinogenesis.
AB
Figure 1 IHC pictures using anti-Src family negative regulatory [pY] site antibody and Clone28 antibody; magnification  400. (A) Illustrates invasive
breast cancer immunohistochemically stained with anti-Src family negative regulatory (pY) site antibody (Invitrogen, 1:1500); moderate staining of nuclei,
weak staining of cell cytoplasm and membrane can be seen. (B) Demonstrates strong perinuclear staining in invasive breast cancer stained with Clone28
antibody (Invitrogen, 1:500).
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